Public Sector Pension Investment Board trimmed its holdings in shares of Xencor Inc (NASDAQ:XNCR) by 11.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 110,532 shares of the biopharmaceutical company’s stock after selling 14,500 shares during the period. Public Sector Pension Investment Board’s holdings in Xencor were worth $3,801,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also bought and sold shares of the stock. First Trust Advisors LP increased its position in Xencor by 185.4% in the 1st quarter. First Trust Advisors LP now owns 69,783 shares of the biopharmaceutical company’s stock worth $2,167,000 after purchasing an additional 45,331 shares during the last quarter. State Street Corp increased its holdings in shares of Xencor by 58.8% during the 3rd quarter. State Street Corp now owns 2,160,578 shares of the biopharmaceutical company’s stock valued at $72,876,000 after acquiring an additional 799,664 shares during the last quarter. EP Wealth Advisors LLC acquired a new position in shares of Xencor during the 3rd quarter valued at about $1,091,000. California State Teachers Retirement System increased its holdings in shares of Xencor by 1.2% during the 3rd quarter. California State Teachers Retirement System now owns 73,722 shares of the biopharmaceutical company’s stock valued at $2,487,000 after acquiring an additional 880 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Xencor during the 3rd quarter valued at about $4,968,000. 93.72% of the stock is currently owned by hedge funds and other institutional investors.
Shares of XNCR stock traded up $1.48 during mid-day trading on Thursday, reaching $30.25. 53,377 shares of the stock traded hands, compared to its average volume of 614,176. The stock’s fifty day simple moving average is $32.18 and its two-hundred day simple moving average is $35.17. Xencor Inc has a 1-year low of $19.35 and a 1-year high of $46.33. The company has a market cap of $1.64 billion, a price-to-earnings ratio of 67.31 and a beta of 1.36. The company has a quick ratio of 8.39, a current ratio of 8.39 and a debt-to-equity ratio of 0.01.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Monday, February 24th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.05. Xencor had a return on equity of 4.23% and a net margin of 17.15%. The company had revenue of $3.52 million during the quarter, compared to the consensus estimate of $6.73 million. On average, equities research analysts anticipate that Xencor Inc will post -1.85 EPS for the current fiscal year.
In other Xencor news, major shareholder John S. Stafford III sold 58,862 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $35.81, for a total value of $2,107,848.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ronin Capital, Llc sold 26,800 shares of the firm’s stock in a transaction that occurred on Thursday, March 19th. The shares were sold at an average price of $28.23, for a total value of $756,564.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 146,538 shares of company stock valued at $5,097,344. 4.33% of the stock is currently owned by corporate insiders.
XNCR has been the topic of a number of analyst reports. Guggenheim raised Xencor from a “neutral” rating to a “buy” rating and set a $43.00 price objective on the stock in a report on Tuesday, February 25th. Mizuho reissued a “buy” rating and set a $52.00 price objective on shares of Xencor in a report on Monday, February 17th. ValuEngine raised Xencor from a “hold” rating to a “buy” rating in a report on Tuesday, March 3rd. Barclays initiated coverage on Xencor in a research note on Wednesday, March 4th. They set an “underweight” rating and a $28.00 target price for the company. Finally, Zacks Investment Research lowered Xencor from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. Xencor presently has an average rating of “Buy” and an average target price of $44.33.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Recommended Story: Discount Rate
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc (NASDAQ:XNCR).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.